← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicstaleMerck Healthcare KGaA, Darmstad…Phase 1

M9140 (M9140)

Solid Tumors; Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
ADCBiologicstaleMinghui Pharmaceutical (Hangzho…Phase 2

MHB036C (MHB036C)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-3120 (MK-3120)

Bladder Cancer · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleMillennium Pharmaceuticals, Inc.Phase 1

MLN0264 (MLN0264)

Advanced Gastrointestinal Malignancies · Advanced Gastrointestinal Malignancies

#AdvancedGastrointestinalMalignan#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 4상태 ACTIVE
ADCBiologicstaleBristol-Myers SquibbPhase 2

MORAb-202 (MORAb-202)

Carcinoma, Non-Small-Cell Lung · Neoplasms, Ovarian

#NeoplasmsOvarian#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 20%임상시험 4상태 DISCONTINUED
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#항체#면역항체+3
효능 ORR 52%임상시험 4상태 ACTIVE
ADCBiologicstaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 3.2%임상시험 4상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
AntibodystaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#항체#면역항체+2
임상시험 4상태 RECRUITING
CGTBiologicstaleElvira UmyarovaPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 4상태 ACTIVE
AntibodystaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
ADCBiologicstaleShanghai Yuansong Biotechnology…Phase 2

YSCH-01 (YSCH-01)

Recurrent Glioblastoma · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystalePeregrine PharmaceuticalsPhase 2

bavituximab (bavituximab)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 9%임상시험 4상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab)

Liver Cancer; Antibody · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 RECRUITING

57 / 209 페이지

← 이전다음 →